Fierce Biotech September 11, 2024
SpectraWAVE has raised $50 million to support its approach to imaging the insides of clogged, plaque-filled blood vessels.
The Massachusetts-based company combines optical coherence tomography and near-infrared spectroscopy—two light-based methods for determining the properties of tissue—into a catheter-based tool that can help surgeons analyze the makeup of coronary artery blockages from within.
SpectraWAVE’s HyperVue system, which received two FDA clearances in 2023, also features an artificial-intelligence-powered program to help measure vessel plaques without contrast agents, to aid surgeons in precisely placing stents during percutaneous coronary interventions.
Its series B funding round was led by Johnson and Johnson Innovation, the conglomerate’s venture capital arm, with additional backing from S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Management, NovaVenture and Heartwork Capital,...
Today's Sponsors
Today's Sponsor